Industry Verticals »

All Categories

Insights »

About TMR »

Cough Hypersensitivity Syndrome Treatment Market

Cough Hypersensitivity Syndrome Treatment Market (Drug Class: Antitussive Agents, Inhaled Corticosteroids, Short Acting Beta-2 Agonists, Anti-cholinergics, Antihistamines, Proton Pump Inhibitors, Others; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Companies Invest in Opiates and GABA-Related Compounds to Treat Cough Hypersensitivity Syndrome

On a global level, the alarming prevalence of chronic cough amongst individuals has propelled healthcare companies in the cough hypersensitivity syndrome treatment market to develop efficacious treatment options. As such, they are increasing their focus on developing improved formulations of antitussive agents. This trend is distinctly true, since antitussive agents are projected to dominate the cough hypersensitivity syndrome treatment market, with an estimated revenue of ~US$ 2.8 billion by 2027.

In order to relieve patients from cough hypersensitivity, healthcare companies are investing in opiates and GABA (gamma-aminobutyric acid)-related compounds. Opiates serve as effective cough suppressants and possess efficacious antitussive properties to treat chronic intractable cough. Likewise, companies are increasing their production capabilities of tramadol, an opioid medication that is similar to the molecular formula of codeine drugs.

Since chronic cough causes increased body pain, companies in the cough hypersensitivity syndrome treatment market are increasing the availability of babapentin and pregabalin, which are GABA-related compounds, and act as neuromodulators for the treatment of neuropathic pain and epilepsy. It has been found in placebo-controlled trials that, gabapentin is well-tolerated for the treatment of refractory chronic cough.

cough hypersensitivity syndrome treatment market infographics

PPI Therapy and Beta Agonists Provide Relief for GERD and Asthma

Healthcare companies in the cough hypersensitivity syndrome treatment space are increasing clinical trials to study the effects of aerosolized capsaicin with behavioral cough suppression. It has been found that, the inhalation of aerosolized capsaicin in gradually increasing doses has contributed to the decrease in cough sensitivity. Healthcare providers have recommended the repetition of the treatment sessions to effectively minimize the instances of cough hypersensitivity.

Chronic cough is associated with high prevalence of gastroesophageal reflux disease (GERD). Hence, companies in the cough hypersensitivity syndrome treatment market are innovating in proton pump inhibitors (PPI) therapy. Proton pump inhibitors currently account for the second-highest revenue share amongst the drugs in the cough hypersensitivity syndrome treatment market. PPI therapy is also effective for diseases related to GERD, such as achalasia, infectious esophagitis, and eosinophilic esophagitis. In order to treat asthma, healthcare providers in the cough hypersensitivity syndrome treatment market are increasing research capabilities in bronchodilators that include short acting beta-2 agonists. They also recommend patients to undergo spirometry to avoid the side effects of beta agonists.

Manufacturers Collaborating with Healthcare Providers to Increase Awareness about Early Upper Endoscopy

The cough hypersensitivity syndrome treatment market is anticipated to grow at a modest CAGR of ~5%. However, the nature of the market is consolidated, which makes it challenging for emerging market players to enter into the bracket of prominent and leading healthcare companies. Although the market is consolidated, the inefficiency of drugs and their adverse effects are negatively affecting market growth.

For instance, voltage-gated sodium channels reduce excitability and sensory nerve activity amongst patients. However, there is a growing need for newer agents that present realistic options for cough hypersensitivity syndrome patients. In many cases, proton pump inhibitors lead to complications of refractory GERD, with recurrence of reflux symptoms. Hence, healthcare companies in the cough hypersensitivity syndrome treatment market should increase awareness about the judicious administration of PPIs. They should team up with healthcare providers who can encourage patients to undergo early upper endoscopy to evaluate new alarm symptoms.

cough hypersensitivity syndrome treatment market segmentation

Analysts’ Viewpoint

New clinical guidelines by health commissions across nations suggest the screening, diagnosis, and treatment of chronic cough at regular intervals. Healthcare companies in the cough hypersensitivity syndrome treatment market should increase their research capabilities to understand pathophysiology for refractory chronic cough.

Antitussive agents are being increasingly used by healthcare providers to treat various complications of cough hypersensitivity. However, certain agents provide no clinical evidence of improvement in the health of patients. As such, there is an increasing need for the optimized clinical evaluation of uncontrolled symptoms and mechanistic understanding of neurobiology to achieve promising therapeutic targets. Market players should introduce more treatment options in anti-inflammatory therapy for patients with cough-variant asthma and eosinophilic bronchitis.

Cough Hypersensitivity Syndrome Treatment Market Description

  • The cough hypersensitivity syndrome treatment market is projected to increase at a CAGR of 5.5%, from a value of ~US$ 7 Bn in 2018 to ~US$ 11 Bn by the year 2027.
  • A range of novel pharmacological approaches, such as P2X3 receptor antagonists (MK-7264) and other concepts are in clinical development for the treatment of cough hypersensitivity syndrome, which would contribute to the growth of the global cough hypersensitivity syndrome treatment market.
  • Cough hypersensitivity syndrome can be defined as a clinical entity in which excessive cough is experienced, triggered by lower levels of mechanical, thermal, and chemical exposure, and characterized by hypersensitivity reactions.
  • Cough hypersensitivity syndrome is caused due to a primary condition characterized by afferent neuronal hypersensitivity. Different aspects of this syndrome are manifested in various phenotypes of cough.
  • A variety of treatment options are available for cough hypersensitivity syndrome, depending upon the cause.
  • The treatment options for cough hypersensitivity syndrome include various drugs that majorly treat three most common causes: asthma, upper airway cough syndrome, and reflux conditions.
  • Antitussive agents are the common drugs used to treat cough hypersensitivity syndrome, owing to their effectiveness in treating cough, and ongoing related clinical trials.
  • All these factors are contributing to the growth of the global cough hypersensitivity syndrome treatment market.

Cough Hypersensitivity Syndrome Treatment Market: Drivers

  • Rise in the prevalence of chronic respiratory diseases is a major factor responsible for the growth of the global cough hypersensitivity syndrome treatment market.
  • Different respiratory diseases and conditions such as chronic obstructive pulmonary disease (COPD), asthma, and allergic rhinitis are some of the major conditions catalyzing the growth of the global cough hypersensitivity syndrome treatment market.
  • Increase in the number of smokers all around the world is a major contributor to the rise in chronic cough hypersensitivity syndrome and related disorders.
  • The high prevalence of unexplained chronic cough associated with Gastroesophageal Reflux Disease (GERD) is also fueling the growth of the global cough hypersensitivity syndrome treatment market.

Cough Hypersensitivity Syndrome Treatment Market: Segment Analysis

  • Increase in the usage of antitussive agents for the treatment of cough hypersensitivity and ongoing research on the development of effective antitussive therapies are leading to the growth of the antitussive agents drug class segment in the global cough hypersensitivity syndrome treatment market.
  • Retail pharmacies are major distribution channels for cough hypersensitivity syndrome treatment drugs. This segment dominated the global cough hypersensitivity syndrome treatment market in 2018, owing to an increase in the number of retail pharmacies in close vicinity to patients, as well as increasing sales of over-the-counter medication for cough treatment through these retail pharmacies.
  • The online pharmacies segment is a lucrative distribution channel segment in the global cough hypersensitivity syndrome treatment market. This is becoming a popular option for patients due to the convenience of online purchasing and numerous options available on online platforms for medicine and price comparison.

Cough Hypersensitivity Syndrome Treatment Market: Major Players

  • The report concludes with the company profiles section that includes key information about major players operating in the cough hypersensitivity syndrome treatment market.
  • Key players analyzed in this report on the global cough hypersensitivity syndrome treatment market are
    • Pfizer, Inc.
    • GlaxoSmithKline plc
    • Boehringer Ingelheim GmbH
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • Merck & Co., Inc.
    • Vertex Pharmaceuticals Incorporated
    • Johnson & Johnson Consumer Inc.
  • In May 2018, GSK received U.S. Food and Drug Administration (FDA) approval for the use of Arnuity Ellipta (fluticasone furoate), a once-daily inhaled corticosteroid (ICS) medicine for the treatment of asthma in children over the age of five years. This makes Arnuity one of the few once-daily treatments for asthma, licensed in the U.S. for this age group.
  • The development of new products through robust R&D activities, global expansion through wide distribution networks, and strategic collaborations & partnerships for business expansion are some of the key strategies adopted by leading players in the cough hypersensitivity syndrome treatment market. Several companies are focusing on the development of new products, which are under clinical trial and in different phases.
  • Each of these players have been profiled in the report on the global cough hypersensitivity syndrome treatment market, based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Frequently Asked Questions

What is the total market worth of cough hypersensitivity syndrome treatment market?

Cough hypersensitivity syndrome treatment market to reach ~US$ 11 Bn by the 2027

What is the anticipated CAGR of the cough hypersensitivity syndrome treatment market in the forecast period?

Cough hypersensitivity syndrome treatment market is projected to increase at a CAGR of 5.5% 2019 - 2027

What are the key driving factors for the growth of the cough hypersensitivity syndrome treatment market?

Cough hypersensitivity syndrome treatment market is driven by rise in the prevalence of chronic respiratory diseases

Which region is expected to project the highest market share in the global cough hypersensitivity syndrome treatment market?

North America dominated the global cough hypersensitivity syndrome treatment market, and is projected to continue its dominance during the forecast period.

Who are the key players in the cough hypersensitivity syndrome treatment market?

Key players in the cough hypersensitivity syndrome treatment market include Pfizer, Inc., GlaxoSmithKline plc, Boehringer Ingelheim GmbH, AstraZeneca, F. Hoffmann-La Roche Ltd.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Cough Hypersensitivity Syndrome Treatment Market 

4. Market Overview

    4.1. Introduction

        4.1.1. Respiratory Drug Classes Definition

        4.1.2. Industry Evolution/Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

    4.5. Porter’s Five Force Analysis

5. Key Insights 

    5.1. Epidemiology Cough hypersensitivity syndrome

    5.2. Pipeline Analysis

6. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, By Drug Class, 2017–2027

        6.3.1. Antitussive Agents

        6.3.2. Inhaled Corticosteroids (ICS)

        6.3.3. Short Acting Beta2-Agonists (SABA)

        6.3.4. Anti-cholinergics

        6.3.5. Antihistamines

        6.3.6. Proton Pump Inhibitors

        6.3.7. Others

    6.4. Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Drug Class 

7. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, By Distribution Channel

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies

    7.4. Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel

8. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, By Region

    8.1. Key Findings

    8.2. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027

        8.2.1. North America 

        8.2.2. Europe 

        8.2.3. Asia Pacific 

        8.2.4. Latin America 

        8.2.5. Middle East & Africa 

    8.3. Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Region  

9. North America Cough Hypersensitivity Syndrome Treatment Market Value Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. North America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027

        9.2.1. Antitussive Agents

        9.2.2. Inhaled Corticosteroids (ICS)

        9.2.3. Short Acting Beta2-Agonists (SABA)

        9.2.4. Anti-cholinergics

        9.2.5. Antihistamines

        9.2.6. Proton Pump Inhibitors

        9.2.7. Others

    9.3. North America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies

    9.4. North America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country, 2017–2027

        9.4.1. U.S.

        9.4.2. Canada

    9.5. North America Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis 

        9.5.1. By Drug Class 

        9.5.2. By Distribution Channel

        9.5.3. By Country

10. Europe Cough Hypersensitivity Syndrome Treatment Market  Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027

        10.2.1. Antitussive Agents

        10.2.2. Inhaled corticosteroids (ICS)

        10.2.3. Short-Acting Beta2-Agonists (SABA)

        10.2.4. Anti-cholinergics

        10.2.5. Antihistamines

        10.2.6. Proton Pump Inhibitors

        10.2.7. Others

    10.3. Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies

        10.3.3. Online Pharmacies

    10.4. Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Europe Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis 

        10.5.1. By Drug Class 

        10.5.2. By Distribution Channel

        10.5.3. By Country

11. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market  Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027

        11.2.1. Antitussive Agents

        11.2.2. Inhaled corticosteroids (ICS)

        11.2.3. Short-Acting Beta2-Agonists (SABA)

        11.2.4. Anti-cholinergics

        11.2.5. Antihistamines

        11.2.6. Proton Pump Inhibitors

        11.2.7. Others

    11.3. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027

        11.3.1. Hospital Pharmacies

        11.3.2. Retail Pharmacies

        11.3.3. Online Pharmacies

    11.4. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis 

        11.5.1. By Drug Class 

        11.5.2. By Distribution Channel

        11.5.3. By Country/Sub-region

12. Latin America Cough Hypersensitivity Syndrome Treatment Market  Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027

        12.2.1. Antitussive Agents

        12.2.2. Inhaled corticosteroids (ICS)

        12.2.3. Short-Acting Beta2-Agonists (SABA)

        12.2.4. Anti-cholinergics

        12.2.5. Antihistamines

        12.2.6. Proton Pump Inhibitors

        12.2.7.  Others

    12.3. Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027

        12.3.1. Hospital Pharmacies

        12.3.2. Retail Pharmacies

        12.3.3. Online Pharmacies

    12.4. Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Latin America Cough Hypersensitivity Syndrome Treatment Market Attractiveness  Analysis 

        12.5.1. By Drug Class 

        12.5.2. By Distribution Channel

        12.5.3. By Country/Sub-region

13. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market  Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027

        13.2.1. Antitussive Agents

        13.2.2. Inhaled corticosteroids (ICS)

        13.2.3. Short-Acting Beta2-Agonists (SABA)

        13.2.4. Anti-cholinergics

        13.2.5. Antihistamines

        13.2.6. Proton Pump Inhibitors

        13.2.7. Others

    13.3. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027

        13.3.1. Hospital Pharmacies

        13.3.2. Retail Pharmacies

        13.3.3. Online Pharmacies

    13.4. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027

        13.4.1. GCC

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis 

        13.5.1. By Drug Class 

        13.5.2. By Distribution Channel

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player – Competition Matrix (By Tier and Size of companies)

    14.2. Market Share Analysis by Company (2018)

    14.3. Company Profiles

        14.3.1. Pfizer, Inc. 

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Financial Overview      

            14.3.1.3. Product Portfolio

            14.3.1.4. Strategic Overview

            14.3.1.5. SWOT Analysis

        14.3.2. GlaxoSmithKline plc

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Financial Overview      

            14.3.2.3. Product Portfolio

            14.3.2.4. Strategic Overview

            14.3.2.5. SWOT Analysis

        14.3.3. Boehringer Ingelheim GmbH 

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Financial Overview      

            14.3.3.3. Product Portfolio

            14.3.3.4. Strategic Overview

            14.3.3.5. SWOT Analysis

        14.3.4. AstraZeneca

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Financial Overview      

            14.3.4.3. Product Portfolio

            14.3.4.4. Strategic Overview

            14.3.4.5. SWOT Analysis

        14.3.5. F. Hoffmann-La Roche Ltd.

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Financial Overview      

            14.3.5.3. Product Portfolio

            14.3.5.4. Strategic Overview

            14.3.5.5. SWOT Analysis

        14.3.6. Teva Pharmaceutical Industries Ltd. 

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Financial Overview      

            14.3.6.3. Product Portfolio

            14.3.6.4. Strategic Overview

            14.3.6.5. SWOT Analysis

        14.3.7. Novartis AG 

            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.7.2. Financial Overview      

            14.3.7.3. Product Portfolio

            14.3.7.4. Strategic Overview

            14.3.7.5. SWOT Analysis

        14.3.8. Merck & Co., Inc. (Merck Sharp & Dohme Corp)

            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.8.2. Financial Overview      

            14.3.8.3. Product Portfolio

            14.3.8.4. Strategic Overview

            14.3.8.5. SWOT Analysis

        14.3.9. Vertex Pharmaceuticals Incorporated 

            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.9.2. Financial Overview      

            14.3.9.3. Product Portfolio

            14.3.9.4. Strategic Overview

            14.3.9.5. SWOT Analysis

        14.3.10. Johnson & Johnson Consumer Inc.

            14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.10.2. Financial Overview      

            14.3.10.3. Product Portfolio

            14.3.10.4. Strategic Overview

            14.3.10.5. SWOT Analysis

List of Tables

Table 01: Pipeline Analysis

Table 02: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 03: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 04: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 05: North America Cough Hypersensitivity Syndrome Treatment market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 06: North America Cough Hypersensitivity Syndrome Treatment market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 07: North America Cough Hypersensitivity Syndrome Treatment market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 08: Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 09: Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 10: Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 11: Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 12: Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 13: Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 14: Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 15: Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 16: Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 17: Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 18: Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 19: Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

List of Figures

Figure 01: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) and Distribution (%), by Region, 2019 and 2027

Figure 02: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2027

Figure 03: Global Cough Hypersensitivity Syndrome Treatment Market Value Share (%), by Drug Class (2019)

Figure 04: Global Cough Hypersensitivity Syndrome Treatment Market Value Share (%), by Distribution Channel (2019)

Figure 05: Global Cough Hypersensitivity Syndrome Treatment Market Value Share (%), by Region (2019)

Figure 06: Porter’s Five Force Analysis– Cough Hypersensitivity Syndrome Treatment Market

Figure 07: Epidemiology of Cough Hypersensitivity Syndrome (Chronic Cough)

Figure 08: Global Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 09: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Antitussive Agents, 2017–2027

Figure 10: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Inhaled Corticosteroids, 2017–2027

Figure 11: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Short acting Beta-2 Agonists, 2017–2027

Figure 12: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Anticholinergics, 2017–2027

Figure 13: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Antihistamines, 2017–2027

Figure 14: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Proton Pump Inhibitors, 2017–2027

Figure 15: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027

Figure 16: Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Drug Class, 2019?2027

Figure 17: Global Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 18: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Hospital Pharmacies, 2017–2027

Figure 19: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Retail Pharmacies, 2017–2027

Figure 20: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Online Pharmacies, 2017–2027

Figure 21: Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Distribution Channel, 2019?2027

Figure 22: Global Cough Hypersensitivity Syndrome Treatment Market: Regional Outlook

Figure 23: Global Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Region, 2018 and 2027

Figure 24: Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Region, 2019–2027

Figure 25: North America Cough Hypersensitivity Syndrome Treatment market Value (US$ Mn) Forecast, 2019–2027

Figure 26: North America Cough Hypersensitivity Syndrome Treatment market Value Share, by Country, 2018 and 2027

Figure 27: North America Cough Hypersensitivity Syndrome Treatment market Attractiveness, by Country, 2019–2027

Figure 28: North America Cough Hypersensitivity Syndrome Treatment market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 29: North America Cough Hypersensitivity Syndrome Treatment market Attractiveness Analysis, by Drug Class, 2019?2027

Figure 30: North America Cough Hypersensitivity Syndrome Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 31: North America Cough Hypersensitivity Syndrome Treatment market Attractiveness, by Distribution Channel, 2019–2027

Figure 32: Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, 2019–2027

Figure 33: Europe Cough Hypersensitivity Syndrome Treatment Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 34: Europe Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 36: Europe Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2019?2027

Figure 35: Europe Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 37: Europe Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 38: Europe Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 39: Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, 2019–2027

Figure 40: Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 41: Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 42: Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 43: Asia Pacific Cough Hypersensitivity Syndrome Market Attractiveness Analysis, by Drug Class, 2019?2027

Figure 44: Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 45: Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 46: Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, 2019–2027

Figure 47: Latin America Cough Hypersensitivity Syndrome Treatment Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 48: Latin America Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 49: Latin America Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 50: Latin America Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2019?2027

Figure 51: Latin America Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 52: Latin America Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 53: Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, 2019–2027

Figure 54: Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 55: Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 56: Middle East & Africa Cough Hypersensitivity Syndrome Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 57: Middle East & Africa Cough Hypersensitivity Syndrome Market Attractiveness Analysis, by Drug Class, 2019?2027

Figure 58: Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 59: Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 60: Pfizer, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 61: Pfizer, Inc. Breakdown of Net Sales (%), by Region, 2018

Figure 62: Pfizer, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 63: Pfizer, Inc. Breakdown of Net Sales (%), by Business Segment, 2018

Figure 64: GSK R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 65: GSK Breakdown of Net Sales (%), by Geography, 2018

Figure 66: GSK Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 67: GSK Breakdown of Net Sales (%), by Business Segment, 2018

Figure 68: Boehringer Ingelheim GmbH R&D Expenditure (US$ Mn), 2016–2018

Figure 69: Boehringer Ingelheim GmbH Breakdown of Net Sales, by Region (Company Level), 2018

Figure 70: Boehringer Ingelheim GmbH Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2018

Figure 71: Boehringer Ingelheim GmbH Breakdown of Net Sales, by Business Segment, 2018

Figure 72: AstraZeneca Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 73: AstraZeneca Breakdown of Net Sales (%), by Region/Country, 2018

Figure 74: AstraZeneca R&D Expenses (US$ Mn), 2015–2018

Figure 75: AstraZeneca Breakdown of Net Sales (%), by Business Segment, 2018

Figure 76: F. Hoffmann-La Roche Ltd. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018

Figure 77: F. Hoffmann-La Roche Ltd. Breakdown of Net Sales, by Business Segment, 2018

Figure 78: F. Hoffmann-La Roche Ltd. Breakdown of Net Sales, by Region, 2018

Figure 79: F. Hoffmann-La Roche Ltd. Research & Development Cost (US$ Mn), 2015–2017

Figure 80: Teva Pharmaceutical Industries Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2018

Figure 81: Teva Pharmaceutical Industries Ltd. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 82: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018

Figure 83: Novartis AG Breakdown of Net Sales, by Region, 2018

Figure 84: Novartis AG R&D Intensity and Sales & Marketing Intensity - Company Level, 2017–2018

Figure 85: Novartis AG Breakdown of Net Sales, by Business Segment, 2018

Figure 86: Merck & Co., Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 87: Merck & Co., Inc. Revenue Breakdown of Net Sales (%), by Segment, 2018

Figure 88: Merck & Co., Inc. Breakdown of Net Sales (%), by Region/Country, 2018

Figure 89: Merck & Co., Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 90: Vertex Pharmaceuticals Incorporated Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 91: Vertex Pharmaceuticals Incorporated Breakdown of Net Sales (%), by Region/Country, 2018

Figure 92: Vertex Pharmaceuticals Incorporated R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 93: Johnson & Johnson Consumer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 94: Johnson & Johnson Consumer Inc. Breakdown of Net Sales (%), by Region, 2018

Figure 95: Johnson & Johnson Consumer Inc. Breakdown of Net Sales (%), by Business Segment, 2018

Copyright © Transparency Market Research, Inc. All Rights reserved

Cough Hypersensitivity Syndrome Treatment Market

Schedule a Call